Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Preferred Stock Liabilities (2016 - 2019)

United Therapeutics (UTHR) has disclosed Preferred Stock Liabilities for 8 consecutive years, with $8.4 million as the latest value for Q2 2019.

  • Quarterly Preferred Stock Liabilities fell 56.25% to $8.4 million in Q2 2019 from the year-ago period, while the trailing twelve-month figure was $8.4 million through Jun 2019, down 56.25% year-over-year, with the annual reading at $19.2 million for FY2018, 0.0% changed from the prior year.
  • Preferred Stock Liabilities hit $8.4 million in Q2 2019 for United Therapeutics, down from $19.2 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $20.4 million in Q1 2015 to a low of $8.4 million in Q2 2019.
  • Historically, Preferred Stock Liabilities has averaged $15.2 million across 5 years, with a median of $16.1 million in 2015.
  • Biggest five-year swings in Preferred Stock Liabilities: plummeted 66.6% in 2015 and later skyrocketed 76.15% in 2017.
  • Year by year, Preferred Stock Liabilities stood at $11.1 million in 2015, then dropped by 1.8% to $10.9 million in 2016, then surged by 76.15% to $19.2 million in 2017, then changed by 0.0% to $19.2 million in 2018, then plummeted by 56.25% to $8.4 million in 2019.
  • Business Quant data shows Preferred Stock Liabilities for UTHR at $8.4 million in Q2 2019, $19.2 million in Q1 2019, and $19.2 million in Q4 2018.